Affinity (Shanghai) Biopharmaceutical Co., Ltd. will present four latest preclinical research findings in the form of poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

As one of the largest and most influential cancer research conferences worldwide, the 2026 AACR Annual Meeting will be held April 17–22 in San Diego, USA. Global oncology experts will attend both in-person and virtually to share and exchange the latest advances in cancer research and therapy.

At this year’s AACR Annual Meeting, Affinity will showcase a series of research advances developed on its proprietary innovative technology platform, covering tumor microenvironment-activated molecular design, dual-payload conjugation strategies, tumor-targeted immune modulation, and in vitro and in vivo efficacy and safety evaluation. These presentations systematically demonstrate the company’s R&D capabilities and innovative achievements spanning molecular design, candidate molecule construction, and preclinical validation.

— Four Preclinical Research Abstracts from Affinity —

1. Novel tumor microenvironment (TME)-activated, pan-RASi and Topo1i dual-payload linker enables safe broad RAS inhibition and overcomes Topo1i resistance

Location: Poster Section 12

Poster Board Number: 4

Poster Number: 4426

Session Date and Time:

Pacific Time (PT): April 21, 9:00 AM – 12:00 PM

Beijing Time (CST): April 22, 00:00 – 03:00

2. Novel ALDC and ADC with TMEA-linker and Eribulin payload demonstrate excellent safety and efficacy in preclinical evaluation

Location: Poster Section 10

Poster Board Number: 24

Poster Number: 5654

Session Date and Time:

Pacific Time (PT): April 21, 2:00 PM - 5:00 PM 

Beijing Time (CST): April 22, 05:00 – 08:00 

3. Novel tumor microenvironment (TME) activated interleukin-2 (IL-2) fused to anti-PD-1 or anti-PD-1/VEGF-A antibodies for enhanced anti-tumor immunity

Location: Poster Section 48

Poster Board Number: 11

Poster Number: 2635

Session Date and Time:

Pacific Time (PT): April 20,9:00 AM - 12:00 PM 

Beijing Time (CST): April 21, 00:00 – 03:00 

4. Tumor microenvironment-activated T-cell engager (TMEA-TCE) targeting Claudin 6 demonstrates efficacy without inducing cytokine release syndrome

Location: Poster Section 48

Poster Board Number: 12

Poster Number: 2636

Session Date and Time:

Pacific Time (PT): April 20,9:00 AM - 12:00 PM 

Beijing Time (CST): April 21,00:00 – 03:00 

About the American Association for Cancer Research (AACR)

The AACR Annual Meeting is a premier global platform for advancing cancer research. Scientists, clinicians, healthcare providers, cancer survivors, patients, and advocates convene annually to share cuttingedge breakthroughs. The congress spans population science, prevention, cancer biology, translational and clinical research, survivor care, and patient advocacy, showcasing the full spectrum of innovative cancer science and medicine.

About Affinity (Shanghai) Biopharmaceutical Co., Ltd. ("Affinity")

Leveraging its globally first-in-class and proprietary Tumor Microenvironment-Activated (TMEA) technology platform, Affinity develops and advances highly selective, low-toxicity innovative anti-cancer drugs. The company is dedicated to solving the toxicity challenges of traditional chemotherapy and targeted therapies, focusing on unmet medical needs in oncology, with the potential to transform traditional treatment approaches and reshape the cancer care paradigm.

Looking ahead, Affinity aims to become a fully integrated biopharmaceutical company with robust manufacturing and commercialization capabilities.

Forward-Looking Statements Disclaimer

This article is provided solely for the purpose of sharing the Company’s recent R&D progress and related academic information. The research results, data and assessments contained herein are based on the Company’s current understanding and publicly available information, and remain subject to change in light of further R&D progress, data updates, market conditions or other relevant factors. Although the Company has exercised reasonable care in preparing this article, nothing herein shall constitute any commitment, representation, warranty, recommendation or advice, and all information shall be subject to the Company’s official disclosures. Unless required by applicable laws, regulations or regulatory rules, the Company undertakes no obligation to update, revise or supplement any content herein.